Sorafenib + mFOLFOX for Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

July 31, 2018

Study Completion Date

December 31, 2019

Conditions
Hepatocellular Cancer
Interventions
DRUG

Leucovorin

200mg/m2 administered IV on Days 1 and 15 of a 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

DRUG

Fluorouracil

5-FU continuous infusion: 2400mg/m2 total (1200mg/m2/d on day 1 and 2) to start on Day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

DRUG

Oxaliplatin

85 mg/m2 IV on Days 1 and 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

DRUG

Sorafenib

400mg po BID continuously for a 2 week lead-in phase and then Days 1-28 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

Trial Locations (3)

02115

Massachusetts General Hospital, Boston

02125

Dana-Farber Cancer Institute, Boston

02215

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01775501 - Sorafenib + mFOLFOX for Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter